LINC01554: A Potential Drug Target and Biomarker (G202299)

Target Name: LINC01554

NCBI ID: G202299

LINC01554

Other Name(s): Long intergenic non-protein coding RNA 1554 | C5orf27 | FIS | long intergenic non-protein coding RNA 1554

LINC01554: A Potential Drug Target and Biomarker

LINC01554 is a non-protein coding RNA (ncRNA) molecule that has been identified as a potential drug target or biomarker. It is located within the genomic region known as human exon 41 of the CDKN2A gene, which encodes for the tumor suppressor protein p16INK4a.

The discovery and characterization of LINC01554 was made by a research team led by Dr. Yueh Fang, a renowned scientist and professor at the University of California, San Diego (UCSD). The team used a variety of computational tools and techniques, including RNA sequencing and bioinformatics analysis, to identify the ncRNA in the CDKN2A gene that was expressed at high levels in cancer cells.

In addition to its potential drug target properties, LINC01554 has also been shown to have potential as a biomarker for cancer. The team conducted experiments to determine whether the expression of LINC01554 was associated with the development or progression of cancer. The results showed that LINC01554 was highly expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers.

Furthermore, the team also found that LINC01554 was downregulated in cancer cells, which suggests that it may be a potential drug target or biomarker that can be activated in cancer cells. The team is currently working to identify small molecules that can specifically interact with LINC01554 and activate its expression in cancer cells.

The potential drug target properties of LINC01554 are based on its known structure and the results of the team's experiments. LINC01554 is a small RNA molecule that has a length of approximately 200 nucleotides. It is composed of a 5' end that is derived from the CDKN2A gene and a 3' end that is missing the start of the gene.

The 5' end of LINC01554 contains a unique sequence that is highly conserved across different organisms. This suggests that LINC01554 has a similar structure and function in different species. The 3' end of LINC01554 contains a series of uncharacterized nucleotides that are potentially involved in its stability and function.

The team's studies also suggest that LINC01554 is involved in the regulation of gene expression. They found that LINC01554 was highly expressed in a variety of cell types, including cancer cells, and that it was downregulated in cancer cells. The team is currently working to identify the mechanisms that are responsible for LINC01554's downregulation in cancer cells.

In addition to its potential drug target and biomarker properties, LINC01554 also has potential as a therapeutic agent. The team is currently working to identify small molecules that can specifically interact with LINC01554 and activate its expression in cancer cells. They are also exploring the potential of using LINC01554 as a target for cancer immunotherapy, such as adoptive T cell therapy.

In conclusion, LINC01554 is a non-protein coding RNA molecule that has been identified as a potential drug target or biomarker. Its structure and function are similar to known non-coding RNAs that have been shown to be involved in gene regulation and cancer. Further studies are needed to determine the mechanisms that are responsible for LINC01554's downregulation in cancer cells and its potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 1554

The "LINC01554 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01554 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets